Altre lingue Adverum Biotechnologies, Inc.

Azioni

ADVM

US00773U2078

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 01/05/2024			Variaz. 5gg	Var. 1 gen.
9,8 ^USD	+0,82%		-3,83%	+30,18%

30/04	ADVERUM BIOTECHNOLOGIES, INC. : prospettiva positiva di HC Wainwright	ZM
29/04	ADVERUM BIOTECHNOLOGIES, INC. : da Mizuho Securities è Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting	25/04
Adverum Biotechnologies Files $200 Million Mixed Shelf	21/03
Adverum Biotechnologies: Q4 Earnings Snapshot	18/03
Adverum Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Adverum Biotechnologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18/03
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates	18/03
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference	28/02
Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors	21/02
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	12/02
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD	08/02
Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD	08/02
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'	05/02
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing	05/02
Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors	05/02
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024	01/02
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer	29/01
Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee	29/01
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society	07/12
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference	28/11
Adverum Biotechnologies: Q3 Earnings Snapshot	09/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Adverum Biotechnologies, Inc.

Azioni

ADVM

US00773U2078

Altre lingue

Filtri